JHS Svendgaard Laboratories Intrinsic Value
JHS Svendgaard Laboratories (JHS) median intrinsic value is ₹18.15 from 3 valuation models (range ₹15–₹18), vs current price ₹7.26 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. For current market price and key ratios, visit JHS share price screener.
JHS Valuation Methods Summary — DCF, Graham Number & P/E
JHS Svendgaard Laboratories intrinsic value across 3 models vs current price ₹7.26 — upside/downside and value range per method. Read JHS dividend yield for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹18.15 | ₹16.34 - ₹19.96 | +150.0% | Book Value/Share: ₹20.11, P/B: 2.5x |
| Revenue Multiple Method | revenue | ₹14.52 | ₹13.07 - ₹15.97 | +100.0% | Revenue/Share: ₹15.17, P/S: 1.5x |
| Simple DCF (5Y) | dcf | ₹18.15 | ₹14.52 - ₹21.78 | +150.0% | CF Growth: 15.0%, Discount: 15% |
JHS Intrinsic Value vs Market Price — All Valuation Models
JHS Svendgaard Laboratories fair value range ₹15–₹18 vs current market price ₹7.26 across 3 valuation models. Analyse JHS FII DII holdings to track promoter, FII and institutional holdings.
JHS Intrinsic Value Analysis — Undervalued or Overvalued?
JHS Svendgaard Laboratories median intrinsic value ₹18.15, current price ₹7.26 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of JHS?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of JHS Svendgaard Laboratories (JHS) is ₹18.15 (median value). With the current market price of ₹7.26, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹14.52 to ₹18.15, indicating ₹14.52 - ₹18.15.
Is JHS undervalued or overvalued?
Based on our multi-method analysis, JHS Svendgaard Laboratories (JHS) appears to be trading below calculated value by approximately 150.0%.
JHS Financial Health — Key Ratios vs Industry Benchmarks
JHS Svendgaard Laboratories financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 7.88 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -9.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -5.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.61x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
JHS Cash Flow Quality — Operating & Free Cash Flow
JHS Svendgaard Laboratories operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-5 Cr | ₹-15 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-9 Cr | ₹-20 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹23 Cr | ₹23 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹-9 Cr | ₹-12 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹12 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |